Case

Beijing kun rui law firm to win "lige" statins major patent cases

2022-09-06

2022年9月6日,***知识产权局作出了58103和58106号专利无效宣告审查决定,分别维持ZL201510299950.3和ZL03819760.X两件中国专利(下称“涉案专利”)的专利权有效。坤瑞律师事务所受专利权人勃林格殷格翰制药两合公司的委托为该系列专利无效案提供法律服务。

On 6 September 2022, * * * The intellectual property office issued examination decisions on patent invalidations nos. 58103 and 58106, maintaining ZL201510299950.3 and ZL03819760, respectively. X the patent rights of the two Chinese patents (hereinafter referred to as“The patents in question”) are valid. Law Firm Kun Rui was commissioned by the patent Boehringer Ingelheim Liang he company to provide legal services for the series of patent invalidation cases.

两涉案专利涉及勃林格公司所开发的重磅抗糖尿病药物“利格列汀”(商品名:欧唐宁®)。利格列汀具有稳定持久的降糖效果,无需根据患者肝肾功能而调整剂量,且不增加心血管风险,这些独特的优势使其成为全球***畅销的抗糖尿病药物之一。此外,中国首批两件重大专利侵权行政裁决案正是依据两涉案专利之一做出的侵权行政裁决,这也使得该系列无效案审查过程及结果持续受到业内的关注。

The patents in question relate to a blockbuster Anti-diabetic medication called “Ligmentin” developed by Boehringer (trade name: o'donnell) . Its stable and long-lasting hypoglycemic effect, no need to adjust the dose according to the patient's liver or kidney function, and no increase in cardiovascular risk make it one of the world's best-selling Anti-diabetic medication. In addition, China's first two major administrative rulings on patent infringement are based on one of the two patents involved in the administrative rulings, which also makes the series of invalid case review process and results continue to receive industry attention.

根据该重大专利侵权行政裁决案的裁决书,广东东阳光药业有限公司和宜昌东阳光长江药业股份有限公司制造、销售、许诺销售利格列汀仿制药的行为分别侵犯了两涉案专利之一即ZL201510299950.3的专利权。其中的宜昌东阳光长江药业股份有限公司,正是本系列无效案的无效宣告请求人。

According to the ruling of the major administrative patent infringement case, the manufacture, sale and promised sale of generic ligliptin by Guangdong Dongyangguang Pharmaceutical Co. , Ltd. and Yichang Dongyangguang Changjiang Pharmaceutical Co. , Ltd. infringed the patent rights of ZL201510299950.3, one of the two patents involved in the case. One of them, Yichang Dongyangguang Changjiang Pharmaceutical Co. , Ltd. , is the applicant for invalid declaration of this series of invalid cases.

该系列无效案的审查过程可谓一波三折。在2021年9月和11月,无效宣告请求人以不符合专利法第22条第3款和第26条第3、4款为由,先后向两涉案专利提起了***轮专利无效宣告请求。坤瑞团队在封新琴律师的带领下对涉案专利和请求人引用的证据进行了充分研究和探讨,根据医药专业知识和相关的法律法规采取了切实有效的争辩策略,在2022年3月21日对***轮专利无效宣告请求举行的口头审理中,坤瑞团队对请求人的各个无效理由和证据进行了有理有据的答辩。在口审后不久请求人撤回了对两涉案专利的***轮无效宣告请求。请求人于2022年4月又对该两涉案专利提起了第二轮无效宣告请求。在对两涉案专利提起的第二轮无效宣告请求中,请求人补充了多个新证据,无效理由依然是专利法第22条第3款和第26条第3、4款。面对对手有备而来的一波又一波的猛烈攻势,坤瑞团队在仔细分析了请求人所提供新的证据之后,进一步调整和优化了答辩策略,在2022年8月16日举行的口头审理中再次充分阐述了涉案专利应当被维持专利有效的理由。

This series of invalid case review process can be described as twists and turns. In September and November of the 2021, the claimant, on the ground of non-compliance with Article 22(3) and Article 26(3) and (4) of the patent law, has filed two patents involved in the case * * round patent invalidation claims. Under the leadership of lawyer Feng xinqin, Kun Rui and his team have conducted a thorough study and discussion on the patents involved and the evidence cited by the petitioner, and have adopted a practical and effective argument strategy based on the medical professional knowledge and relevant laws and regulations, during the oral hearing on 21 March 2022 on the application for annulment of the * * * round of patents, the Kunrui team presented a reasoned response to the various grounds and evidence of the applicant for annulment. Shortly after the oral hearing, the petitioner withdrew its request for annulment of the two patents in question. In April 2022, the claimant filed a second round of invalidation claims against the two patents in question. In the second round of claims for invalidation of the two patents in question, the claimant added several new pieces of evidence, the grounds for invalidity still being Article 22, paragraph 3, and Article 26, paragraphs 3 and 4, of the patent law. Faced with waves of fierce attacks prepared by their opponents, the Kunrui team further adjusted and optimized their defense strategy after carefully analyzing the new evidence provided by the petitioner, at the oral hearing held on 16 August 2022, the reasons why the patent in question should be maintained were once again fully elaborated.

***知识产权局专利复审无效部合议组于2022年9月6日作出了无效决定,维持两涉案专利全部有效。

* * * on 6 September 2022, the joint panel of the Patent Review Invalidation Department of the Intellectual Property Office (IPO) made an invalid decision, maintaining the validity of all the two patents involved.

作为一家在生命科学知识产权领域深耕多年、始终致力于维护原创知识产权的专业性涉外律师事务所,坤瑞团队很欣喜地看到,在***大力推行知识产权战略的今天,对于知识产权的保护力度也越来越大。知识产权保护在医药领域尤为重要,每一款重磅药物面世的背后,不但凝聚着研发人员的智慧和汗水,更要面对漫长的研发周期、巨额的研发成本。尊重原研,保护原创,药物领域的专利不应轻易被宣告无效。有效保护原创和鼓励原研是人间正道,保护知识产权就是在保护人类社会的未来,没有原创和原研,就没有科技的进步。只有当智力成果能够得到真正的保护,大家才有动力和资金进行科学研究,去不断推动科技进步和社会发展。

As a professional foreign-related law firm with many years of experience in the field of intellectual property rights in life sciences and dedicated to safeguarding original intellectual property rights, the Kun Rui team is very pleased to see that, today, with the vigorous implementation of the intellectual property strategy, the protection of intellectual property rights is getting stronger and stronger. Intellectual property protection is particularly important in the field of medicine. Behind every blockbuster drug, not only the wisdom and sweat of R & D personnel, but also facing a long r & D cycle and huge R & D costs. Respect for original research, protection of original, pharmaceutical patents should not be easily declared invalid. To protect original creation and encourage original research is the right path in the world. To protect intellectual property is to protect the future of human society. Without original creation and original research, there will be no progress in science and technology. Only when the intellectual achievements can be truly protected, can we have the motivation and funds to carry out scientific research, to constantly promote scientific and technological progress and social development.

承办该系列案的坤瑞团队人员包括:

The project team includes:

封新琴律师

Lawyer Feng Xinqin

郭杰专利代理师

Guo Jie is a patent agent

关祥宇律师

Guan Xiangyu, solicitor

 

 

封新琴

Feng xinqin

所长,创始合伙人,律师,专利代理师。从事知识产权行业26年。国际保护知识产权协会(AIPPI)医药专业委员会原联席主席现常委,现中国分会医药专业委员会主席,入选“IAM Patent 1000”***律师榜单。其代理的“热稳定的葡糖淀粉酶”专利相关的专利侵权和专利无效案件等多件案件曾入选“中国法院10大知识产权案件”、“年度十大知识产权案例”等。

Director, founding partner, attorney, patent attorney. Engaged in intellectual property industry for 26 years. The former co-chairman of Aippi Medical Professional Committee is now the Standing Committee member, and the Chairman of the Medical Professional Committee of Aippi China Branch is selected into the list of“IAM Patent 1000”* * * lawyers. The“Heat-stable glucoamylase” patent-related patent infringement and patent invalidation cases have been listed in the“Chinese Court 10 top intellectual property cases”, “The year 10 top intellectual property cases” and so on.

大连理工大学工学硕士和工学学士,美国马歇尔法学院知识产权法LL.M.,民商法硕士。

Master of Dalian University of Technology and Bachelor of Engineering, Intellectual Property Law ll. M. Master of Civil and commercial law.

 

郭杰

Guo Jie

专利代理师,从事知识产权行业15年。北京大学药学院理学硕士和理学学士。

Patent agent, engaged in intellectual property industry for 15 years. Master of Science and Bachelor of Science, School of Pharmacy, Peking University.

 

关祥宇

Guan Xiangyu

律师,专利代理师,从事知识产权行业11年。北京大学药学院理学硕士和理学学士。

Lawyer, patent agent, engaged in intellectual property industry for 11 years. Master of Science and Bachelor of Science, School of Pharmacy, Peking University.